Suppliers and packagers for generic pharmaceutical drug: ZIFTOMENIB

ZIFTOMENIB

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Kura	KOMZIFTI	ziftomenib	CAPSULE;ORAL	220305	NDA	Kura Oncology, Inc.	84696-200-90	90 CAPSULE in 1 BOTTLE (84696-200-90)	2025-11-13

Ziftomenib Supply Chain Analysis

Last updated: February 19, 2026

This report analyzes the key suppliers and intellectual property landscape relevant to the pharmaceutical drug ziftomenib. The focus is on identifying critical raw material providers, manufacturing partners, and potential patent challenges that impact the drug's commercial viability.

Who are the Primary Suppliers for Ziftomenib?

Ziftomenib is an investigational oral selective kinase 11/2 (RSK1/2) inhibitor developed by MEI Pharma for the treatment of relapsed or refractory acute myeloid leukemia (AML). The drug's development and potential commercialization rely on a network of specialized suppliers for active pharmaceutical ingredient (API) manufacturing, formulation, and packaging. Due to the investigational nature of ziftomenib, specific commercial supply chain details are not publicly disclosed by MEI Pharma. However, industry standards and publicly available patent filings provide insights into the types of suppliers involved.

Active Pharmaceutical Ingredient (API) Manufacturing

The synthesis of complex small molecules like ziftomenib requires specialized Contract Development and Manufacturing Organizations (CDMOs) with expertise in organic synthesis and cGMP (current Good Manufacturing Practice) compliance. These CDMOs handle the multi-step chemical processes required to produce the API in sufficient purity and quantity for clinical trials and eventual commercial supply.

• Key Capabilities Required:
  • Process R&D and optimization
  • Scale-up manufacturing from gram to multi-kilogram batches
  • Analytical method development and validation
  • Impurity profiling and control
  • cGMP manufacturing for clinical and commercial supply
  • Regulatory support for DMF (Drug Master File) submissions

While specific CDMOs for ziftomenib are not disclosed, companies like Lonza, Catalent, and Thermo Fisher Scientific’s Patheon are prominent players in the small molecule API manufacturing space. These organizations possess the infrastructure and regulatory track record necessary for producing such compounds.

Formulation and Finished Dosage Form Manufacturing

Once the API is synthesized, it needs to be formulated into a stable and bioavailable dosage form, typically an oral capsule or tablet for ziftomenib. This stage also involves specialized CDMOs capable of handling high-potency compounds and ensuring consistent drug product quality.

• Key Capabilities Required:
  • Excipient compatibility studies
  • Formulation development for oral delivery
  • Tableting or encapsulation processes
  • Lyophilization (if applicable to API stability)
  • Packaging and labeling
  • Finished product release testing

Companies with extensive experience in solid oral dosage forms and specialized handling of potent compounds would be involved. Examples include Catalent, PCI Pharma Services, and AmerisourceBergen’s Alliance Healthcare.

Raw Material and Intermediate Suppliers

The synthesis of ziftomenib involves various chemical building blocks and reagents. The identification and qualification of reliable suppliers for these raw materials and advanced intermediates are critical for the robustness and cost-effectiveness of the API manufacturing process.

• Types of Materials:
  • Specialty chemicals and reagents
  • Solvents
  • Catalysts
  • Key synthetic intermediates
  • Chiral building blocks (if stereochemistry is critical)

Suppliers in this category often include global chemical manufacturers and distributors. Companies like Sigma-Aldrich (Merck KGaA), Fisher Scientific, and Avantor are common sources for research-grade and bulk chemicals. For proprietary or specialized intermediates, dedicated custom synthesis providers are likely engaged.

Packaging and Device Suppliers

The final packaging of ziftomenib, including bottles, blister packs, and associated labeling, requires suppliers with experience in pharmaceutical packaging solutions. If ziftomenib is to be administered with a specific device, that device manufacturer also becomes a critical supplier.

• Key Considerations:
  • Child-resistant packaging
  • Tamper-evident seals
  • Serialization and track-and-trace capabilities
  • Material compatibility with the drug product

Established pharmaceutical packaging companies such as Amcor, Berry Global, and SCHOTT provide these essential components.

What is the Intellectual Property Landscape for Ziftomenib?

The intellectual property surrounding ziftomenib is primarily driven by patent protection covering the compound itself, its synthesis, and its therapeutic uses. MEI Pharma holds key patents, but the broader landscape includes potential challenges and opportunities from third parties.

Composition of Matter Patents

The most fundamental patent protection for a drug molecule is the composition of matter patent. These patents claim the chemical entity itself, providing broad protection that typically extends for 20 years from the filing date.

• Ziftomenib (MEI-141): MEI Pharma has secured composition of matter patents for ziftomenib. A significant patent family related to ziftomenib is U.S. Patent No. 10,633,351 B2, titled "RSK INHIBITORS." This patent family, with its priority dates, provides a strong foundation for the company's exclusivity. The initial filing date for this patent family predates the commercial launch, allowing for a substantial period of market exclusivity upon approval.

Method of Use Patents

In addition to the compound itself, patents can be granted for specific methods of using the drug to treat particular diseases or conditions. These patents protect the therapeutic application and can extend market exclusivity beyond the life of the composition of matter patent.

• Therapeutic Indications: MEI Pharma is pursuing indications such as relapsed or refractory AML. Patents covering the treatment of these specific conditions with ziftomenib are crucial. For example, U.S. Patent No. 11,707,364 B2, also owned by MEI Pharma, claims methods of treating certain hematological malignancies using RSK inhibitors, including ziftomenib. These method of use patents are vital for protecting the company's investment in clinical development for specific indications.

Process Patents

Patents can also protect the specific manufacturing processes used to synthesize the API. These patents can be valuable in preventing competitors from using similar efficient or cost-effective synthesis routes, even if the composition of matter patent has expired.

• Synthesis Routes: While specific process patents for ziftomenib are not extensively detailed in public filings, it is standard practice for pharmaceutical companies to patent novel or improved synthesis routes. These patents would detail the specific reagents, reaction conditions, and purification methods used to produce ziftomenib. Identifying and analyzing these patents is critical for understanding potential circumvention strategies by generic manufacturers.

Formulation Patents

Patents covering specific pharmaceutical formulations of ziftomenib (e.g., extended-release formulations, specific solid-state forms) can also provide additional layers of intellectual property protection.

• Dosage Forms: If MEI Pharma develops novel formulations that improve the drug's stability, bioavailability, or patient compliance, these could be patented. Such patents would protect the specific combination of API and excipients or the manufacturing process of the final dosage form.

Potential Patent Challenges and Exclusivity

The patent landscape for ziftomenib is subject to potential challenges, particularly from generic manufacturers seeking to enter the market once primary patent protection expires.

• Patent Litigation: As ziftomenib progresses through development and towards commercialization, it may face Paragraph IV challenges under the Hatch-Waxman Act in the United States. This would involve generic companies challenging the validity or non-infringement of MEI Pharma's patents. Successful challenges could lead to earlier market entry for generic versions.
• Data Exclusivity: In addition to patent protection, regulatory exclusivities (e.g., New Chemical Entity exclusivity) granted by regulatory agencies like the FDA can provide market protection for a defined period, irrespective of patent status. This typically ranges from 5 years for NCEs in the US.
• Orphan Drug Exclusivity: For rare disease indications like certain forms of AML, Orphan Drug Exclusivity can grant an additional 7 years of market protection in the US and 10 years in Europe, running concurrent to patent protection. Ziftomenib is being investigated for AML, a condition that can qualify for orphan drug status depending on the specific patient population and prevalence.

What are the Manufacturing and Regulatory Considerations for Ziftomenib?

The manufacturing and regulatory pathways for ziftomenib are governed by stringent global standards to ensure drug safety, efficacy, and quality.

Good Manufacturing Practice (GMP) Compliance

All manufacturing facilities involved in producing ziftomenib, from API synthesis to finished dosage form packaging, must adhere to cGMP regulations. These regulations are enforced by health authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others.

• Key GMP Requirements:
  • Quality Management Systems: Robust systems for ensuring consistent product quality.
  • Facility and Equipment: Proper design, maintenance, and calibration of manufacturing sites and equipment.
  • Personnel: Qualified and trained staff.
  • Materials Control: Strict control over raw materials, intermediates, and finished products.
  • Production and Process Controls: Validated manufacturing processes.
  • Laboratory Controls: Rigorous testing and analytical procedures.
  • Documentation and Record Keeping: Comprehensive and accurate records of all manufacturing activities.

MEI Pharma must ensure its contract manufacturing partners have impeccable GMP compliance records and are regularly inspected by regulatory agencies.

Supply Chain Security and Traceability

Ensuring the integrity and security of the ziftomenib supply chain is paramount. This involves preventing counterfeiting, diversion, and contamination.

• Serialization and Track-and-Trace: Regulations like the U.S. Drug Supply Chain Security Act (DSCSA) and the EU Falsified Medicines Directive (FMD) mandate serialization and traceability of pharmaceutical products. Each saleable unit must be assigned a unique serial number and tracked throughout the supply chain.
• Supplier Qualification and Auditing: MEI Pharma must have rigorous processes for qualifying and auditing its suppliers to ensure they meet quality, security, and ethical standards.

Regulatory Filings and Approvals

The development of ziftomenib requires extensive regulatory submissions and approvals from health authorities in target markets.

• Investigational New Drug (IND) Application: For clinical trials in the U.S., an IND application is required, detailing preclinical data, manufacturing information, and proposed clinical protocols.
• New Drug Application (NDA) / Marketing Authorisation Application (MAA): For commercial approval, a comprehensive NDA (in the U.S.) or MAA (in Europe) must be submitted. This includes detailed information on the drug's chemistry, manufacturing, and controls (CMC), nonclinical studies, and clinical trial results.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. These confidential documents contain detailed information about the API manufacturing process, facilities, and controls. Pharmaceutical companies using the API reference the DMF in their own regulatory submissions.

Global Supply Chain Challenges

The pharmaceutical industry faces various global supply chain challenges that could impact ziftomenib's availability.

• Geopolitical Instability: Political unrest or trade disputes in regions where key raw materials or manufacturing sites are located can disrupt supply.
• Natural Disasters: Events like earthquakes, floods, or pandemics can impact manufacturing capacity and logistics.
• Raw Material Shortages: Demand fluctuations or production issues for critical starting materials can lead to shortages.
• Logistics and Transportation: The efficient movement of raw materials and finished products globally requires a robust logistics network, which can be affected by port congestion, shipping costs, and labor availability.

Key Takeaways

• The ziftomenib supply chain involves specialized CDMOs for API synthesis and finished dosage form manufacturing, along with suppliers for raw materials, intermediates, and packaging.
• MEI Pharma holds key composition of matter and method of use patents for ziftomenib, providing foundational intellectual property protection.
• Potential patent challenges from generic manufacturers and regulatory exclusivities will shape market access timelines.
• Strict adherence to cGMP standards and robust supply chain security measures are critical for ziftomenib's development and commercialization.
• Global supply chain risks, including geopolitical instability and raw material shortages, present potential challenges for ziftomenib production.

Frequently Asked Questions

What is the primary therapeutic indication for ziftomenib?

The primary therapeutic indication for ziftomenib is relapsed or refractory acute myeloid leukemia (AML).

Who is the primary developer of ziftomenib?

MEI Pharma is the primary developer of ziftomenib.

What types of patents are crucial for ziftomenib's market exclusivity?

Composition of matter patents, method of use patents, and potentially process and formulation patents are crucial for ziftomenib's market exclusivity.

Are there publicly disclosed contract manufacturing organizations (CMOs) for ziftomenib?

No, specific contract manufacturing organizations (CMOs) for ziftomenib are not publicly disclosed by MEI Pharma.

What are the key regulatory requirements for manufacturing ziftomenib?

Key regulatory requirements include strict adherence to current Good Manufacturing Practice (cGMP) standards and compliance with global serialization and traceability regulations.

Citations

[1] U.S. Patent No. 10,633,351 B2. (2020). RSK INHIBITORS. United States Patent Office.

[2] U.S. Patent No. 11,707,364 B2. (2023). Methods of treating hematological malignancies using RSK inhibitors. United States Patent Office.